Tolterodine ( DrugBank: Tolterodine )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 17 | 多系統萎縮症 | 1 |
| 53 | シェーグレン症候群 | 1 |
17. 多系統萎縮症
臨床試験数 : 118 / 薬物数 : 163 - (DrugBank : 49) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 112
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100046394 | 2021-06-01 | 2021-05-15 | Research of Pelvic Floor Electrical Stimulation for Defecation and Urination Dysfunction in Patients with Multiple System Atrophy | Research of Pelvic Floor Electrical Stimulation for Defecation and Urination Dysfunction in Patients with Multiple System Atrophy | multiple system atrophy | Experimental group:Drug (tolterodine) combined with electrical stimulation; | Xuanwu Hospital, Capital Medical University | NULL | Recruiting | 30 | 75 | Both | Experimental group:50; | N/A | China |
53. シェーグレン症候群
臨床試験数 : 283 / 薬物数 : 320 - (DrugBank : 101) / 標的遺伝子数 : 56 - 標的パスウェイ数 : 181
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04909255 (ClinicalTrials.gov) | March 23, 2021 | 21/4/2021 | Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder | The Therapeutic Effect of Beta-3 Agonist and Anti-muscarinic Agent on Overactive Bladder Among Sjogren's Syndrome Patient | Sjogren's Syndrome;Overactive Bladder Syndrome | Drug: mirabegron;Drug: oxybutynin, tolterodine, solifenacin | China Medical University Hospital | NULL | Recruiting | 20 Years | N/A | All | 50 | Phase 4 | Taiwan |